PD-L1 (Programmed Death Ligand 1) as a Marker of Acute Cellular Rejection After Heart Transplantation.
作者信息
Choudhary Arrush, Brinkley D Marshall, Besharati Sepideh, Meijers Wouter C, Atkinson James B, Amancherla Kaushik, Zhu Qingfeng, Huang Shi, Nguyen Lee S, Salem Joe-Elie, Ammirati Enrico, Lindenfeld JoAnn, Anders Robert A, Moslehi Javid
机构信息
Division of Cardiology (A.C., D.M.B., W.C.M., K.A., J.-E.S., J.L., J.M.), Vanderbilt University Medical Center, Nashville, TN.
Cardio-Oncology Program (A.C., W.C.M., K.A., J.-E.S., J.M.), Vanderbilt University Medical Center, Nashville, TN.
出版信息
Circ Heart Fail. 2021 Oct;14(10):e008563. doi: 10.1161/CIRCHEARTFAILURE.121.008563. Epub 2021 Sep 24.
Abstract
摘要
相似文献
1
PD-L1 (Programmed Death Ligand 1) as a Marker of Acute Cellular Rejection After Heart Transplantation.程序性死亡配体1（PD-L1）作为心脏移植后急性细胞排斥反应的标志物
Circ Heart Fail. 2021 Oct;14(10):e008563. doi: 10.1161/CIRCHEARTFAILURE.121.008563. Epub 2021 Sep 24.
2
Programmed Death-Ligand 2 Deficiency Exacerbates Experimental Autoimmune Myocarditis in Mice.程序性死亡配体 2 缺乏加剧了小鼠实验性自身免疫性心肌炎。
Int J Mol Sci. 2021 Jan 31;22(3):1426. doi: 10.3390/ijms22031426.
3
Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.利用 22C3 抗程序性死亡配体 1 抗体检测非小细胞肺癌患者细胞学样本中的程序性死亡配体 1 表达。
Cancer Cytopathol. 2018 Apr;126(4):264-274. doi: 10.1002/cncy.21977. Epub 2018 Feb 7.
4
Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.体内CD4和CD8 T细胞介导的同种异体免疫反应中负性T细胞共刺激途径的作用分析
J Immunol. 2005 Jun 1;174(11):6648-56. doi: 10.4049/jimmunol.174.11.6648.
5
Programmed death-1 targeting can promote allograft survival.程序性死亡-1靶向治疗可促进同种异体移植物存活。
J Immunol. 2002 Dec 1;169(11):6546-53. doi: 10.4049/jimmunol.169.11.6546.
6
Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction.供体 PD-L1 与受者 PD-1 相互作用对人肝移植物排斥反应活性的反向调节。
J Hepatol. 2016 Jun;64(6):1274-82. doi: 10.1016/j.jhep.2016.02.034. Epub 2016 Mar 3.
7
The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response.化疗对程序性细胞死亡蛋白1/程序性细胞死亡蛋白1配体轴的影响：一些化疗药物最终可能通过免疫反应发挥作用。
Oncotarget. 2016 May 17;7(20):29794-803. doi: 10.18632/oncotarget.7631.
8
Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors.全面深入了解在实体瘤中表达程序性死亡受体 1/程序性死亡配体 1 的免疫细胞的作用及调控机制。
Cancer Biol Med. 2020 Aug 15;17(3):626-639. doi: 10.20892/j.issn.2095-3941.2020.0112.
9
Checkpoint blockade after kidney transplantation.肾移植后的检查点阻断
Eur J Cancer. 2018 Jun;96:111-114. doi: 10.1016/j.ejca.2018.03.019. Epub 2018 Apr 26.
10
Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.肝细胞癌中的程序性细胞死亡蛋白 1（PD-1）/程序性死亡配体 1（PD-L1）轴：预后和治疗展望。
Clin Transl Oncol. 2019 Jun;21(6):702-712. doi: 10.1007/s12094-018-1975-4. Epub 2018 Nov 1.
引用本文的文献
1
Elevated PD-L1 and PECAM-1 as Diagnostic Biomarkers of Acute Rejection in Lung Transplantation.PD-L1和PECAM-1升高作为肺移植急性排斥反应的诊断生物标志物
Transpl Int. 2024 Nov 21;37:13796. doi: 10.3389/ti.2024.13796. eCollection 2024.
2
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart.免疫检查点抑制剂相关性心肌炎：心脏中的 CTLA4、PD1 和 LAG3。
Nat Rev Cancer. 2024 Aug;24(8):540-553. doi: 10.1038/s41568-024-00715-5. Epub 2024 Jul 9.
3
Spatially resolved immune exhaustion within the alloreactive microenvironment predicts liver transplant rejection.在同种异体反应性微环境中，空间分辨的免疫衰竭可预测肝移植排斥。
Sci Adv. 2024 Apr 12;10(15):eadm8841. doi: 10.1126/sciadv.adm8841.
4
Fine-tuning tumor- and allo-immunity: advances in the use of immune checkpoint inhibitors in kidney transplant recipients.微调肿瘤免疫和同种异体免疫：肾移植受者使用免疫检查点抑制剂的进展
Clin Kidney J. 2024 Mar 9;17(4):sfae061. doi: 10.1093/ckj/sfae061. eCollection 2024 Apr.
5
Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure.心肌生理学和病理学中的免疫检查点：心力衰竭的治疗靶点。
Nat Rev Cardiol. 2024 Jul;21(7):443-462. doi: 10.1038/s41569-023-00986-9. Epub 2024 Jan 26.
6
Spatially resolved immune exhaustion within the alloreactive microenvironment predicts liver transplant rejection.同种异体反应性微环境内的空间分辨免疫耗竭可预测肝移植排斥反应。
Res Sq. 2023 Jul 3:rs.3.rs-3044385. doi: 10.21203/rs.3.rs-3044385/v1.
7
[Tc]-labelled anti-Programmed Death-Ligand 1 single-domain antibody SPECT/CT: a novel imaging biomarker for myocardial PD-L1 expression.[锝]标记的抗程序性死亡配体1单域抗体SPECT/CT：一种用于心肌程序性死亡配体1表达的新型成像生物标志物。
EJNMMI Res. 2023 May 17;13(1):44. doi: 10.1186/s13550-023-00990-7.
8
Circulating immune checkpoints predict heart failure outcomes.循环免疫检查点可预测心力衰竭结局。
ESC Heart Fail. 2023 Aug;10(4):2330-2337. doi: 10.1002/ehf2.14304. Epub 2023 Apr 25.
9
Risk Factors for Immune Checkpoint Inhibitor-Mediated Cardiovascular Toxicities.免疫检查点抑制剂相关心血管毒性的危险因素。
Curr Oncol Rep. 2023 Jul;25(7):753-763. doi: 10.1007/s11912-023-01414-4. Epub 2023 Apr 20.
10
Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis.急性心肌炎和复发性/急性心包炎的免疫调节治疗
Front Med (Lausanne). 2022 Mar 7;9:838564. doi: 10.3389/fmed.2022.838564. eCollection 2022.
本文引用的文献
1
Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms.免疫检查点抑制剂相关心肌炎：表现与机制。
J Clin Invest. 2021 Mar 1;131(5). doi: 10.1172/JCI145186.
2
Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma.基线血清PD-1或PD-L1水平升高预示着转移性黑色素瘤患者接受PD-1抑制治疗的预后较差。
Ann Oncol. 2020 Jan;31(1):144-152. doi: 10.1016/j.annonc.2019.09.005.
3
PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison.黑色素瘤中程序性死亡受体配体1（PD-L1）的表达：定量免疫组织化学抗体比较
Clin Cancer Res. 2017 Aug 15;23(16):4938-4944. doi: 10.1158/1078-0432.CCR-16-1821. Epub 2017 Apr 20.
4
Fulminant Myocarditis with Combination Immune Checkpoint Blockade.暴发性心肌炎合并免疫检查点阻断治疗
N Engl J Med. 2016 Nov 3;375(18):1749-1755. doi: 10.1056/NEJMoa1609214.
5
Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection.1990年心脏排斥反应诊断命名标准化工作方案的修订版。
J Heart Lung Transplant. 2005 Nov;24(11):1710-20. doi: 10.1016/j.healun.2005.03.019. Epub 2005 Jun 20.
Zotero 插件